Researchers at Keck Medicine of the University of Southern California (USC) have discovered that combining immunotherapy with laser heat therapy could significantly extend the survival of individuals diagnosed with deadly brain cancers such as glioblastoma. The findings, published in a recent study, offer new hope for patients with these aggressive tumors, which typically have a poor prognosis.
Laser interstitial thermal therapy (LITT) is a minimally invasive procedure that uses heat to destroy tumor tissue. When combined with immunotherapy, which harnesses the body's immune system to fight cancer, the dual approach appears to enhance the immune response against the tumor. The study, conducted at USC's Keck School of Medicine, demonstrated that patients who received both treatments had markedly improved survival rates compared to those who received standard therapies.
Glioblastoma is the most common and aggressive malignant brain tumor in adults, with a median survival of about 15 months after diagnosis. Current standard treatment includes surgery, radiation, and chemotherapy, but recurrence is almost inevitable. The new combination therapy aims to address this by not only destroying the primary tumor but also stimulating an immune response that can target residual cancer cells throughout the brain.
Companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also engaged in developing novel treatments for brain cancers. CNS Pharmaceuticals is focused on developing therapies for primary brain tumors and central nervous system (CNS) cancers. The company's lead candidate, Berubicin, is a novel anthracycline designed to cross the blood-brain barrier and has shown promise in clinical trials for glioblastoma.
The USC study adds to a growing body of evidence that combination therapies may be key to improving outcomes for brain cancer patients. By integrating multiple treatment modalities, researchers hope to overcome the resistance mechanisms that often limit the effectiveness of single-agent therapies.
More information about the study and ongoing research can be found at the Keck Medicine of USC website and through BioMedWire, a specialized communications platform covering developments in the biotechnology and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @IBN, offering access to a vast network of wire solutions and article syndication to over 5,000 outlets.
The full terms of use and disclaimers for BioMedWire content are available on their website at https://www.BioMedWire.com/Disclaimer. For more information on the latest in biomedical research, visit https://www.BioMedWire.com.
